APSR2026-904

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-013
P32
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1240557-46904-Research_433610.pdf
Format: PDF Only
08. Lung Cancer
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Boqiang Wang * Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Kejing Yang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Hai Pan - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Lingping Kong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
 
 
 
 
 
 
 
 
 
Presenting Author Details
Boqiang
Wang
wmyc4733897@163.com
+8618322005185
Under 30
China
Original Research
Development and Validation of a Nomogram for Predicting Time to Resistance Following First-Line Osimertinib in EGFR-Mutant Lung Adenocarcinoma
Maximum 25 words
Abstract Content
Osimertinib has become the standard first-line treatment for advanced EGFR-mutant lung adenocarcinoma and has demonstrated substantial clinical efficacy. However, acquired resistance remains a major limitation to its long-term therapeutic benefit. For non–high-risk patients initially treated with osimertinib monotherapy, accurate prediction of the timing of resistance development is crucial for individualized therapeutic decision-making. This study aimed to develop and validate a predictive model for estimating the potential median time to resistance following osimertinib monotherapy.
We retrospectively enrolled patients with advanced or postoperative recurrent metastatic stage IV EGFR-mutant lung adenocarcinoma who received first-line osimertinib treatment. Eligible cases were selected according to predefined inclusion and exclusion criteria. Clinical characteristics, EGFR mutation subtypes, alterations in EGFR downstream signaling pathway–related genes, and other genomic profiling data were collected. Univariate analysis was performed using the Weibull regression model, and variables with P < 0.1 were incorporated into a multivariable nomogram model. Model performance was evaluated using the concordance index (C-index) and calibration curves.
A total of 87 patients with complete clinical and genomic data were included in the final analysis. Univariate Weibull regression identified TP53 mutation subtype, EGFR mutation subtype, mutations in EGFR downstream signaling pathways, gender, PD-L1 expression, tumor mutational burden (TMB), brain metastasis, carcinoembryonic antigen (CEA) level, pleural metastasis, and multiorgan metastasis as factors associated with time to resistance (P < 0.1); these variables were subsequently incorporated into the nomogram model. The model achieved a C-index of 0.79. Calibration curves comparing predicted median progression-free survival (mPFS) with observed mPFS closely approximated the 45° reference line, indicating good predictive accuracy and consistency.
This model enables quantitative and visualized assessment of osimertinib resistance risk, providing a theoretical basis for optimizing individualized intermittent and combination therapeutic strategies, while assisting clinicians in estimating patient-specific resistance time windows.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
 
maximum 3 keywords and no abbreviations, separated by commas
 
292